164 related articles for article (PubMed ID: 25697760)
1. Methodological aspects of the molecular and histological study of prostate cancer: focus on PTEN.
Ugalde-Olano A; Egia A; Fernández-Ruiz S; Loizaga-Iriarte A; Zuñiga-García P; Garcia S; Royo F; Lacasa-Viscasillas I; Castro E; Cortazar AR; Zabala-Letona A; Martín-Martín N; Arruabarrena-Aristorena A; Torrano-Moya V; Valcárcel-Jiménez L; Sánchez-Mosquera P; Caro-Maldonado A; González-Tampan J; Cachi-Fuentes G; Bilbao E; Montero R; Fernández S; Arrieta E; Zorroza K; Castillo-Martín M; Serra V; Salazar E; Macías-Cámara N; Tabernero J; Baselga J; Cordón-Cardo C; Aransay AM; Villar AD; Iovanna JL; Falcón-Pérez JM; Unda M; Bilbao R; Carracedo A
Methods; 2015 May; 77-78():25-30. PubMed ID: 25697760
[TBL] [Abstract][Full Text] [Related]
2. Rapid in vivo validation of candidate drivers derived from the PTEN-mutant prostate metastasis genome.
Cho H; Herzka T; Stahlhut C; Watrud K; Robinson BD; Trotman LC
Methods; 2015 May; 77-78():197-204. PubMed ID: 25592467
[TBL] [Abstract][Full Text] [Related]
3. Combined MYC Activation and Pten Loss Are Sufficient to Create Genomic Instability and Lethal Metastatic Prostate Cancer.
Hubbard GK; Mutton LN; Khalili M; McMullin RP; Hicks JL; Bianchi-Frias D; Horn LA; Kulac I; Moubarek MS; Nelson PS; Yegnasubramanian S; De Marzo AM; Bieberich CJ
Cancer Res; 2016 Jan; 76(2):283-92. PubMed ID: 26554830
[TBL] [Abstract][Full Text] [Related]
4. Additive Effect of Zfhx3/Atbf1 and Pten Deletion on Mouse Prostatic Tumorigenesis.
Sun X; Xing C; Fu X; Li J; Zhang B; Frierson HF; Dong JT
J Genet Genomics; 2015 Jul; 42(7):373-82. PubMed ID: 26233892
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer.
Wang S; Gao J; Lei Q; Rozengurt N; Pritchard C; Jiao J; Thomas GV; Li G; Roy-Burman P; Nelson PS; Liu X; Wu H
Cancer Cell; 2003 Sep; 4(3):209-21. PubMed ID: 14522255
[TBL] [Abstract][Full Text] [Related]
6. Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis.
Ma X; Ziel-van der Made AC; Autar B; van der Korput HA; Vermeij M; van Duijn P; Cleutjens KB; de Krijger R; Krimpenfort P; Berns A; van der Kwast TH; Trapman J
Cancer Res; 2005 Jul; 65(13):5730-9. PubMed ID: 15994948
[TBL] [Abstract][Full Text] [Related]
7. The pace of prostatic intraepithelial neoplasia development is determined by the timing of Pten tumor suppressor gene excision.
Luchman HA; Benediktsson H; Villemaire ML; Peterson AC; Jirik FR
PLoS One; 2008; 3(12):e3940. PubMed ID: 19081794
[TBL] [Abstract][Full Text] [Related]
8. SLUG is a direct transcriptional repressor of PTEN tumor suppressor.
Uygur B; Abramo K; Leikina E; Vary C; Liaw L; Wu WS
Prostate; 2015 Jun; 75(9):907-16. PubMed ID: 25728608
[TBL] [Abstract][Full Text] [Related]
9. Prostate cancer induced by loss of Apc is restrained by TGFβ signaling.
Bjerke GA; Pietrzak K; Melhuish TA; Frierson HF; Paschal BM; Wotton D
PLoS One; 2014; 9(3):e92800. PubMed ID: 24651496
[TBL] [Abstract][Full Text] [Related]
10. Proteomic and transcriptomic profiling of Pten gene-knockout mouse model of prostate cancer.
Zhang J; Kim S; Li L; Kemp CJ; Jiang C; Lü J
Prostate; 2020 May; 80(7):588-605. PubMed ID: 32162714
[TBL] [Abstract][Full Text] [Related]
11. Klf5 deletion promotes Pten deletion-initiated luminal-type mouse prostate tumors through multiple oncogenic signaling pathways.
Xing C; Ci X; Sun X; Fu X; Zhang Z; Dong EN; Hao ZZ; Dong JT
Neoplasia; 2014 Nov; 16(11):883-99. PubMed ID: 25425963
[TBL] [Abstract][Full Text] [Related]
12. Temporally controlled ablation of PTEN in adult mouse prostate epithelium generates a model of invasive prostatic adenocarcinoma.
Ratnacaram CK; Teletin M; Jiang M; Meng X; Chambon P; Metzger D
Proc Natl Acad Sci U S A; 2008 Feb; 105(7):2521-6. PubMed ID: 18268330
[TBL] [Abstract][Full Text] [Related]
13. Collision tumors revealed by prospectively assessing subtype-defining molecular alterations in 904 individual prostate cancer foci.
Fontugne J; Cai PY; Alnajar H; Bhinder B; Park K; Ye H; Beg S; Sailer V; Siddiqui J; Blattner-Johnson M; Croyle JA; Noorzad Z; Calagua C; MacDonald TY; Axcrona U; Bogaard M; Axcrona K; Scherr DS; Sanda MG; Johannessen B; Chinnaiyan AM; Elemento O; Skotheim RI; Rubin MA; Barbieri CE; Mosquera JM
JCI Insight; 2022 Feb; 7(4):. PubMed ID: 35050902
[TBL] [Abstract][Full Text] [Related]
14. LZTS2 and PTEN collaboratively regulate ß-catenin in prostatic tumorigenesis.
Yu EJ; Hooker E; Johnson DT; Kwak MK; Zou K; Luong R; He Y; Sun Z
PLoS One; 2017; 12(3):e0174357. PubMed ID: 28323888
[TBL] [Abstract][Full Text] [Related]
15. Loss of CCAAT-enhancer-binding protein alpha (CEBPA) is linked to poor prognosis in PTEN deleted and TMPRSS2:ERG fusion type prostate cancers.
Minner S; Lutz J; Hube-Magg C; Kluth M; Simon R; Höflmayer D; Burandt E; Tsourlakis MC; Sauter G; Büscheck F; Wilczak W; Steurer S; Schlomm T; Huland H; Graefen M; Haese A; Heinzer H; Jacobsen F; Hinsch A; Poos A; Oswald M; Rippe K; König R; Schroeder C
Prostate; 2019 Feb; 79(3):302-311. PubMed ID: 30430607
[TBL] [Abstract][Full Text] [Related]
16. Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development.
Jiao J; Wang S; Qiao R; Vivanco I; Watson PA; Sawyers CL; Wu H
Cancer Res; 2007 Jul; 67(13):6083-91. PubMed ID: 17616663
[TBL] [Abstract][Full Text] [Related]
17. Molecular alterations of EGFR and PTEN in prostate cancer: association with high-grade and advanced-stage carcinomas.
de Muga S; Hernández S; Agell L; Salido M; Juanpere N; Lorenzo M; Lorente JA; Serrano S; Lloreta J
Mod Pathol; 2010 May; 23(5):703-12. PubMed ID: 20208477
[TBL] [Abstract][Full Text] [Related]
18. PTEN loss mediated Akt activation promotes prostate tumor growth and metastasis via CXCL12/CXCR4 signaling.
Conley-LaComb MK; Saliganan A; Kandagatla P; Chen YQ; Cher ML; Chinni SR
Mol Cancer; 2013 Jul; 12(1):85. PubMed ID: 23902739
[TBL] [Abstract][Full Text] [Related]
19. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues.
Suzuki H; Freije D; Nusskern DR; Okami K; Cairns P; Sidransky D; Isaacs WB; Bova GS
Cancer Res; 1998 Jan; 58(2):204-9. PubMed ID: 9443392
[TBL] [Abstract][Full Text] [Related]
20. A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer.
Ahearn TU; Pettersson A; Ebot EM; Gerke T; Graff RE; Morais CL; Hicks JL; Wilson KM; Rider JR; Sesso HD; Fiorentino M; Flavin R; Finn S; Giovannucci EL; Loda M; Stampfer MJ; De Marzo AM; Mucci LA; Lotan TL
J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26615022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]